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Objective: A systematic review of randomized controlled trials was conducted to examine the efﬁcacy of
ﬁbrin sealants for the reduction of postoperative blood loss and allogeneic red blood cell transfusion in
total knee arthroplasty (TKA).
Methods: Studies published through May 2013 were identiﬁed from PubMed, Embase, the Cochrane
library, ScienceDirect, and other databases. Two independent reviewers assessed the quality of meth-
odology using the Grade of Recommendations Assessment, Development and Evaluation approach and
extracted data from literature. The mean difference (MD) of blood loss, hemoglobin loss, and risk ratios
(RR) of transfusion rate and adverse events in the ﬁbrin-treated and placebo groups were pooled
throughout the study. The relevant data were analyzed using Stata 11.0 software.
Results: Eight studies were included in the review, with a total sample size of 558 patients. The drainage
blood loss [MD ¼ 354.02 mL, 95% conﬁdence interval (CI) (500.87 to 207.18); P < 0.05], reduction in
calculated total blood loss [MD ¼ 402.12, 95% CI (599.16 to 205.08); P < 0.05], hemoglobin loss
[MD ¼ 0.86 g/dL, 95% CI (1.10 g/dL to 0.61 g/dL); P < 0.05], and transfusion rate [RR ¼ 0.62, 95% CI
(0.45e0.86); P < 0.05] were all signiﬁcantly reduced following treatment with ﬁbrin sealants. There were
no signiﬁcant differences in the incidence of adverse events [RR ¼ 0.69, 95% CI (0.32e1.59); P > 0.05]
among the study groups.
Conclusions: The results of the present meta-analysis suggest that ﬁbrin sealants for patients undergoing
TKA may reduce blood loss and maintain higher hemoglobin levels, particularly when ﬁbrin sealants are
used at higher dosage. Furthermore, ﬁbrin sealants do not increase the risk of postoperative deep vein
thrombosis, superﬁcial infection, pulmonary embolism, and hematoma. Further evaluation is required to
conﬁrm our ﬁndings before ﬁbrin sealants can be used in patients undergoing TKA.
Level of evidence: II.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.5,6Total knee arthroplasty (TKA) is an effective orthopedic treat-
ment that has been commonly practiced since its introduction in
the late 1960s. TKA is associated with signiﬁcant perioperative
blood loss, ranging from 500 to 1500 mL, necessitating the trans-
fusion of 1e2 units of allogenic blood in 10%e38% of patients.1e4
Decreasing this postoperative blood loss could potentially reduce
patient morbidity, length of hospitalization, and costs involved by
eliminating the need for transfusion, which is associated with
adverse immunological reactions, disease transmission, intravas-
cular hemolysis, transfusion-induced coagulopathy, renals, General Hospital of Tianjin
þ86 13512233114; fax: þ86
).
ciates Ltd. Published by Elsevier Ltimpairment or failure, and increased mortality. Various blood
preservation techniques following TKA that can reduce the expo-
sure to allogeneic blood have been described. These include
controlled autologous blood transfusion; hypotension; epidural
anesthesia; compression bandage; cryotherapy; and the adminis-
tration of various intravenous (IV), intra-articular, and oral medi-
cations.7e10 However, safer and more effective interventions are
required to reduce the incidence of blood transfusions during and
immediately after TKA.
The use of dry plasma11 and ﬁbrin patches12 at the injury site to
reduce blood loss dates back to the beginning of the twentieth
century. These treatment modalities are the predecessors of the
modern concept of treatment with ﬁbrin sealants, also known as
ﬁbrin glues and ﬁbrin tissue adhesives. The use of ﬁbrin sealants
formed by plasma ﬁbrinogen mixed with thrombin was ﬁrstd. All rights reserved.
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REVIEWreported during World War II.13 Fibrin sealants used as topical
agents14 consist of plasma ﬁbrinogen mixed with thrombin to form
a ﬁbrin clot adhesive, which mimic the last step of the coagulation
cascade: thrombin activates ﬁbrinogen to polymerize to form an
unstable clot, which is then stabilized by activated factor XIII in the
ﬁbrinogen concentrate by catalyzing the cross-linkage between the
ﬁbrin molecules. Factor XIIIa also cross-links between natural
plasmin inhibitors that prevent ﬁbrinolysis, because of which some
sealants contain additional ﬁbrinolytic inhibitors such as bovine
aprotinin or tranexamic acid (TXA). The ﬁbrin may also function in
blood loss prevention by sealing and plugging the bone marrow
sinusoids; furthermore, it may prevent extravasation from the cut
edges of tissues by suppressing enhanced ﬁbrinolysis.15
Yasukawa and Takizawa reported that the ﬁbrin sealant and TXA
of the intra-articular as ‘cocktail’ given were hemostatic agents;
therefore, the reduction in blood loss could not solely be attributed
to the ﬁbrin glue.16 Another study reported that human ﬁbrin
sealant Quixil used in patients undergoing total knee replacement
(TKR) probably reduced the blood loss and transfusion rate without
increasing the incidence of adverse events.17 Many studies have
reviewed ﬁbrin sealants, and ﬁbrin tissue adhesive is used in all
ﬁelds of surgery such as prostatectomy,18 partial pulmonary exci-
sion,19 carotid endarterectomy20 and hepatectomy with liver
mobilization. However, due to the absence of clear evidence con-
cerning the safety and efﬁcacy of ﬁbrin sealants, most commercial
ﬁbrin sealants have not been approved by the Food and Drug
Administration in the United States. Indeed, blood-bank products
and bovine thrombin concentrates, which have considerably lessFig. 1. Flowchart of thsafety than commercial products, are used extensively in the United
States.15
This article aimed to report a meta-analysis of the published
randomized controlled trials investigating the effectiveness of
ﬁbrin sealants used in patients undergoing TKA and to establish
whether it is an efﬁcient product to reduce blood loss, transfusion
rate, and related complications.
1. Material and methods
1.1. Study design
A meta-analysis and systematic review was conducted accord-
ing to the guidelines predeﬁned by the Cochrane Collaboration
(2008).21 All the data were reported according to the Quality of
Reporting for meta-analyses provided by the Handbook for Sys-
tematic Reviews of Interventions version 5.0.22
1.2. Search strategy
Relevant studies published from their establishment to May 22,
2013, were extracted from the Cochrane Central Register of
Controlled Trials (CENTRAL), PubMed, EMBASE, and the ISI Wed of
Knowledge databases by using themedical subject heading (MeSH)
terms “ﬁbrin sealant” OR “total knee arthroplasty” to maximize the
search speciﬁcity and sensitivity. As presented in Fig. 1, only pub-
lished, unpublished and ongoing trials on human subjects that
attempted to gather information on ﬁbrin sealants or TKA weree study selection.
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REVIEWselected for the review. In addition, Google search was used to
manually search for articles from authorities such as the European
Federation of National Associations of Orthopedics and the British
Orthopedic Association Annual Congress, to obtain articles that
may have been missed in the database search. Furthermore, the
reference lists of all the full-text papers were reviewed to identify
any initially omitted studies and restrictions on the language of the
publication.
1.3. Selection criteria and quality assessment
Randomized controlled trials that met the following criteria
were selected for the review: (i) participants received ﬁbrin sealant
treatment; (ii) studies contained a placebo (control) group; (iii)
reported outcomes included postoperative total blood loss (pri-
mary outcomes); and (iv) reported outcomes speciﬁed hemoglobin
loss, number of patients receiving allogeneic blood transfusion, and
incidence of deep vein thrombosis (DVT; secondary outcomes). The
methodological quality of each RCT was assessed using Cochrane
Collaboration’s tool for assessing risk of bias. The tool consists of the
following seven aspects: (i) details of the randomization method,
(ii) allocation concealment, (iii) blinding of participants and
personnel, (iv) blinding of outcome assessment, (v) incomplete
outcome data, (vi) selective outcome reporting, and (vii) other
sources of bias, to provide a qualiﬁcation of risk of bias.
1.4. Data extraction
The search strategy was independently implemented by two
authors (J. Liu and L. Wang) to select references from the above-
mentioned databases. The authors screened the article titles and
abstracts according to the eligibility criteria. The full texts of the
articles that met the inclusion criteria were thoroughly reviewed.
Disagreements were resolved by discussion to reach a consensus.
Authors of the studies were contacted for missing data or further
information when required. The following data were extracted
from the articles: (i) demographic data of the study participants;
(ii) indication for ﬁbrin sealant; (iii) total blood loss, postoperative
blood loss, hemoglobin loss, and the percentage of postoperative
patients who received allogeneic blood transfusion and experi-
enced thromboembolic complications; and (iv) any other potential
interest mentioned in the individual studies. In the case of studies
that contained incomplete or unclear data, we attempted to contact
the investigators for clariﬁcation.
1.5. Data analysis and statistical methods
The extracted data were pooled for summary estimates using
Stata 10.1 for Windows (StataCorp LP, College Station, TX).
Continuous outcomes were recorded as means with standard de-
viation (SD) and group size for each trial arm. The mean difference
(MD) was measured consistently in the trials, with values <0 fa-
voring ﬁbrin sealant. Dichotomous data were expressed as pro-
portions or risks, with the treatment effect reported as a relative
risk ratio (RR). Both kinds of outcomes were reported with 95% CI. A
probability of p < 0.05 was considered statistically signiﬁcant to
summarize ﬁndings across the trials. Statistical heterogeneity for
each study was assessed using a standard chi-square test with
signiﬁcance set at a P value of 0.1, with calculated I value, where
I2 > 50% was considered suggestive of substantial heterogeneity,
prompting a random effects model. Otherwise, a ﬁxed-effects
model was used for the analysis. If any heterogeneity was
observed, the causes of heterogeneity were ﬁrst analyzed and then
subjected to subgroup treatment. If statistical heterogeneity could
not be eliminated, a random effect model was used for thecombined analysis of the studies to examine the clinical consis-
tency. The publication bias complemented with Egger’s regression
and Begg’s rank correlation tests (P > 0.10) assessed by visual in-
spection of the funnel plot.23,242. Results
2.1. Search results
The search strategy identiﬁed 30 citations, among which 8
satisﬁed the predeﬁned inclusion criteria and had been conducted
in the United Kingdom (n ¼ 2), Italy (n ¼ 2), Germany (n ¼ 1),
Northern Ireland (n¼ 1), Denmark (n¼ 1), and United States (n¼ 1;
Fig.1). Eight independent randomized controlled trials published in
English17,25e31 reporting a total of 558 patients at the ﬁnal follow-
up were selected for data extraction and meta-analysis (Table 1).
Of the 558 patients in these studies, 256 patients belonged to the
ﬁbrin sealant group and 302, to the control group.2.2. Study characteristics and quality assessment
As shown in Table 1, all the trials performed were for primary
TKA. There were no signiﬁcant differences in the preoperative
baseline information between the ﬁbrin sealant and control groups.
The majority of trials included in the analysis were small studies
with 24e50 participants.
In each study, ﬁbrin sealant was administered in varying doses
(ranging from 2 to 20mL) while suturing,Wemade a trial29 divided
into two parts due to different doses (5 ml and 10 ml) of ﬁbrin
sealant. TXA was used as the stabilizer in four17,29e32 studies and
multiple doses of sealant (5e10 mL) were used in one study.29 A
total of ﬁve studies had a blank control group of which included
two studies26,28 evaluated administration of TXA as well as 1
study28 had postoperative blood recovery and reinfusion as control
group. Three studies26,29,30 reported a transfusion trigger, which
was related to a fall in either hemoglobin or hematocrit levels. In
one study,17 a transfusion trigger was reported on the basis of the
criteria and guidelines of the National Institutes of Health
Consensus Conference. The blood transfusion protocol was not
mentioned in four studies. Three studies25,27,29 used enoxaparin for
prophylaxis against deep vein thrombosis (DVT) and pulmonary
embolism (PE), and two studies17,30 used low-molecular-weight
heparin. Two studies28,31 did not use any chemical prophylaxis
while one study26 used aspirin as a prophylactic measure. Six
studies recorded the time to deﬂation of the tourniquet17,26,27,29e31;
of these, the tourniquet was released after hemostasis of the visible
blood vessels was established in three studies17,27,31 and before
hemostasis in the other three. Postoperative drainage was
measured in six of the eight studies17,25,27,29e31 and hemoglobin
loss was measured in ﬁve studies,17,25,26,29,30 of which blood loss
was calculated in three.17,26,28 Adverse events were reported in all
studies, and included DVT, pulmonary embolism, and superﬁcial
infection. Postoperative functional recovery was recorded as range-
of-motion (ROM) in two studies27,29 which were not analyzed due
to insufﬁcient data.
According to the Cochrane Collaboration guidelines, the quality
of the randomized clinical trials provided a qualiﬁcation of risk of
bias. Five studies25e27,29,30 lacked information concerning random
sequence generation and allocation concealment; however, these
studies referred to randomization. Five studies17,25,27,29,30 did not
mention that the outcome assessment was blinded. Therefore,
there was a moderate risk of bias in seven studies17,25e30 and low
risk of bias in one.31
Table 1
Characteristics of included studies.
Study
(year)
Country of origin Patients
(FS/Con)
Mean age
(year)
FS group
(source)
Congroup DVT prophylaxis Time to deﬂated
tourniquet
Outcomes Risk of bias
Levy
(1999)17
United Kingdom 29/29 68.9/70.2 10e20 ml
FS
(Quixil Evicel)
Blank LMWH 1 1,2,3,6,7,8 Moderate
Wang
(2001)25
United state 25/28 NA 10 ml FS
(Quixil Evicel)
Blank LMWH NA 1,3,6,8 Moderate
Molloy
(2007)26
Northern Ireland 50/100 NA 10 ml
FS(NA)
Wih TXA
TXA and blank aspirin 2 2,5,6,7,8,
10
Moderate
McConnell
(2010)28
United Kingdom. 21/44 NA 10 ml FS
(Quixil Evicel)
TXA
And
blank
NA NA 3,4,5,6,7,8 Moderate
Kluba
(2012)27
German 12/12 70.8/71.0 2 ml FS
(Quixil Evicel)
with TXA
Blank LMWH 1 1,2,3,6,8,9 Moderate
Notarnicola
(2012)29
Italy 30/30 55e85 10 ml or 5ml FS
(Quixil Evicel)
With TXA
Blank LMWH 2 1,2,3,4,6,8,9 Moderate
Sabatini
(2012)30
Italy 35/35 70.4/70.7 10 ml FS
(Quixil Evicel)
reinfusion LMWH 2 1,2,3,6,8 Moderate
Skovgaard
(2013)31
Denmark 24/24 65 (33e81) 10 ml FS (Evicel) Saline NA 1 1,4,5,6,8,
10
Low
Time to deﬂated the: 1. After hemostasis of visible blood vessels was achieved 2. Before hemostasis of visible blood vessels was achieved tourniquet Outcomes: 1. Mount of
drainage 2. Amounts of transfusion 3. Decreased Hb 4.range of motion 5. VAS 6. Rate of transfusion 7. Calculated blood loss 8. Adverse events 9. Postoperative Hb 10. Leg
swelling NA, not available; TXA, Tranexamic acid.
LMWH, low-molecular-weight heparin; FS, ﬁbrin sealant.
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REVIEW2.3. Publication bias
Publication bias was accessed using Begg’s (P ¼ 0.695) and
Egger’s (P ¼ 0.695) tests. The funnel plot was symmetrical (Fig. 7),
indicating the absence of either positive or negative publication
bias and the non-signiﬁcance of ﬁndings from published studies.
3. Effects of intervention
3.1. Blood loss
A total of eight trials17,25e31 containing 558 patients, which
provided postoperative blood loss data, measured external blood
loss as the volume contained in the drain, and total calculated blood
loss, were reviewed in this study.
A total of six trials17,25,27,29e31 provided data on the effect of
ﬁbrin sealant on blood loss in the drain, indicating that blood loss
was lower in the ﬁbrin sealant group (185 patients) by a mean
volume of 354.02 mL as compared with the control group (158
patients), (95% CI; e500.87 to 207.18 mL; P < 0.01; Fig. 2) with
signiﬁcant heterogeneity (I2 ¼ 93.5%). The calculated total blood
loss was examined in three studies17,26,28 and it was found to be
signiﬁcantly lower in the ﬁbrin sealant group (100 patients) by a
mean volume of 402.12 mL than in the control group (101 pa-
tients), (95% CI; e599.16 mL to 205.08 mL; P < 0.01) with a large
heterogeneity (I2 ¼ 74.7%; Fig. 4). Data of the total hemoglobin loss
were available for ﬁve trials,17,25,26,29,30 211 patients in ﬁbrin sealant
group compared 184 patients in control group, and TXA showed a
positive effect in preventing hemoglobin loss by a mean volume
of 0.86 g/dL (95% CI; e1.10 to 0.61 g/dL; P < 0.01) with a high I2
value of 61.7% (Fig. 3).
3.2. Need for transfusion
All the eight trials,17,25e31 which used various types of ﬁbrin
sealants, reported data on postoperative exposure to allogeneic
blood transfusion. In this section, the authors of this paper
compared the transfusion rate among trials with differentinterventions such as computer-assisted surgery-TKR (CAS-TKR)
[26], different anticoagulants to avoid DVT, such as enox-
aparin25,27,29 and low-molecular-weight heparin (LMWH),17,30 and
using TXA as a stabilizer and having a transfusion trigger.
The pooled number of patients in all the studies that required
transfusion after surgery was 22.2% and 33.6% in the ﬁbrin sealant
(256 patients) and control groups (230 patients), respectively. The
number of patients requiring transfusion did not signiﬁcantly differ
between the groups [RR¼ 0.62, 95% CI (0.45e0.86); P< 0.05]. There
was no evidence of statistical heterogeneity in the ﬁndings (I2¼ 0%;
Fig. 5).3.3. Adverse effects
Six trials described adverse events such as deep vein throm-
bosis, superﬁcial infection, pulmonary embolism, and hematoma.
Four studies17,26,27,29 report DVT complications. It was found that
the use of ﬁbrin sealant was not associated with an increased risk of
DVT (RR ¼ 0.67, 95% CI (0.19e2.35); P > 0.05] and only two
studies25,30 reported PE [RR ¼ 1.01, 95% CI (0.11e9.49); P > 0.05] in
two patients in each group. Superﬁcial infection [RR ¼ 1.05, 95% CI
(0.20e5.49); P > 0.05] was recorded in three patients each in the
ﬁbrin sealant and control groups in three studies.17,26,27 Hematoma
was reported in two studies17,26 [RR ¼ 0.34, 95% CI (0.09e1.25);
P > 0.05]. The total rate of adverse events showed no obvious
change [RR ¼ 0.72, 95% CI (0.32e1.59), P > 0.05] between the ﬁbrin
sealant and control groups. There was no evidence of heterogeneity
between trials (I2 ¼ 0%; Fig. 6).4. Discussion
In this systematic review of eight articles comparing the clinical
results of ﬁbrin sealant with blank groups, we tried to make
deﬁnitive conclusions about the optimal treatment of TKA for
reducing the postoperative blood loss and transfusion rate. Our
studies suggested that the ﬁbrin sealant reduced the amount of
total blood loss, drainage loss, calculated total hemoglobin loss, and
Fig. 2. Forest plot diagram showing the effect of ﬁbrin sealant on drain blood loss. CI, conﬁdence interval; df, degrees of freedom; MeH, ManteleHaenszel.
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infection, PE, and hematoma.
Because of the challenges clinicians face from the lack of ran-
domized surgical trials, we set up with this systematic review
which was identiﬁed as the ﬁrst one to evaluate the use of ﬁbrin
sealant in TKA by only including studies that have appropriate
control and study groups. We sought to broadly address the major
clinically relevant questions regarding ﬁbrin sealant therapy for the
treatment of TKA. Beyond that, we also wanted to avoid pitfalls
which encountered in some prior meta-analyses, such as assess-
ment of bleeding without noting initial hemostasis, failure to ac-
count for total calculated blood loss, use of terms such as drainageFig. 3. Forest plot diagram showing the effect of ﬁbrin sealant on Hb loss. Cblood loss and total calculated blood loss loosely and inter-
changeably, and unwarranted combinations of studies of different
types of therapies together in one analysis. Therefore We tried to
choose total calculated blood loss, drainage blood loss total, he-
moglobin loss, transfusion rate and adverse events as clinically
relevant end points.
The primary signiﬁcant result of this review was that the
administration injection of ﬁbrin sealant consistently reduced the
total calculated blood loss, drainage blood loss, and the total he-
moglobin loss in the majority of the studies analyzed. The results
revealed that TXA signiﬁcantly reduced the total calculated blood
loss, drain blood loss and hemoglobin loss following ﬁbrin sealantI, conﬁdence interval; df, degrees of freedom; MeH, ManteleHaenszel.
Fig. 4. Forest plot diagram showing the effect of ﬁbrin sealant on calculated total blood loss. CI, conﬁdence interval; df, degrees of freedom; MeH, ManteleHaenszel.
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in the body ﬂuid, and is much safer to administer than homologous
blood that cannot be virally inactivated.20 And the addition of tra-
nexamic acid to the ﬁbrin tissue adhesive as a ﬁbrinolytic inhibitor
may play an additive role in the stability of the glue reported in
some included studies.15,33,34 It is reported that ﬁbrin sealant
applied in patients undergoing TKA shows efﬁcacy at doses of 2e
20 ml and the higher concentration of thrombin in the particular
preparation of ﬁbrin tissue adhesive creates a ﬁbrin sealant that
clots faster.29 Subgroup analysis of the different dosages used in the
study was not carried out due to the small sample size and insuf-
ﬁcient data required for further conﬁrmation. Acute anemia (lowFig. 5. Forest plot diagram showing the effechemoglobin) sometimes leads to tachycardia and hypotension, and
can increase the risk of myocardial infarction and blood transfusion
is thus necessary for more severe degrees of anemia. In this meta-
analysis, we found that the transfusion rates after TKA signiﬁcantly
differed between the treatment and control groups in four trials;
however, the protocols involved in these studies were not
mentioned. Heterogeneity may have been caused at the greater risk
of all types of biases because of variations in patient characteristics,
different strategies for measuring outcomes, and the different
methods used to measure postoperative blood loss.
Theoretically, ﬁbrin sealant carries a risk of thrombosis,
although this has not been clinically proven. However, our reviewt of ﬁbrin sealant on blood transfusion.
Fig. 6. Forest plot diagram showing the effect of ﬁbrin sealant on adverse events.
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there were fewer PEs in the ﬁbrin sealant group than in the control
group (2 versus 3). The results of our study suggest that the use of
ﬁbrin sealants in TKA reduces the postoperative inapparent blood
loss that permeates into the tissues to form hematoma. Therefore,
ﬁbrin sealants may reduce the infection rate and promote healing.
However, the present results did not demonstrate decreased risks
of hematoma or superﬁcial infection, only showed a decreasing
trend from the ﬁbrin sealant group towards the control group.
Three fundamental problems may be partly responsible for these
pooled results. First, there is a lack of consensus on the deﬁnition of
hematoma and superﬁcial infection, and second, some authors
detect hematoma on the clinical grounds of palpable ﬂuid collec-
tionwhile others used ultrasound to examine thewound site; theseBegg's funnel plot with pseudo 95% confidence limits
R
R
s.e. of: RR
0 .5 1 1.5
-2
0
2
4
Fig. 7. Begg’s funnel plot displaying a symmetric shape.different detection methods could potentially have inﬂuenced the
reported incidence of hematoma; in addition, small sample size
and insufﬁcient data may not shown the difference between two
group.
Previous meta-analyses have indicated the relationship be-
tween ﬁbrin sealant and postoperative seroma after breast and
axillary surgery, and analyzed the efﬁcacy and safety of ﬁbrin
sealant.32 A meta-analysis set up by Carless suggested that ﬁbrin
sealants are efﬁcacious and can reduce the rate of allogeneic blood
transfusion and blood loss. However, the trials were small and of
poor methodological quality, and transfusion practices may have
been inﬂuenced by knowledge of the patient’s treatment status due
to lack of blinding.35 Another meta-analysis established to evaluate
the safety and clinical efﬁcacy of ﬁbrin glue in pterygium surgery
revealed that ﬁbrin glue was associated with a signiﬁcantly
decreased operating time that may reduce blood loss.36
This meta-analysis has several limitations. First, the statistical
efﬁcacy could be improved by including more studies. Only ﬁve
studies reported the speciﬁc methods of randomization without
referring to random sequence generation and allocation conceal-
ment, thereby introducing selection bias, and in ﬁve studies the
assessors were not blinded to the surgical procedures, which may
have allowed further measurement and expectation biases and the
potential for type II statistical errors in measurements of clinical
outcomes. Secondly, invisible bleeding was rarely measured as
many kinds of methods were employed to estimate bleeding. It is
likely that these inconsistencies across all studies contributed to
the high values seen in statistical analyses. Thirdly, the functional
outcome or quality of life outcome measures could not be analyzed
due to insufﬁcient data, and pooled data in this review could not
fully support the view that increased the rate of transfusion
complication. In addition, the intervention is not completely
J. Liu et al. / International Journal of Surgery 12 (2014) 95e102102
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control groups, which presented challenges in assessing the value
of ﬁbrin sealant alone. Finally, there was some evidence for possible
publication bias, where smaller trials with null ﬁndings might have
been missing from our analysis (Fig. 3). Accordingly, this meta-
analysis should be considered as conviction.
5. Conclusion
Meta-analysis of the current literature revealed that ﬁbrin
sealant reduced the amount of total blood loss, drainage loss,
calculated total hemoglobin loss and transfusion rate. However,
there were no signiﬁcant differences in the rate of DVT, superﬁcial
infection, PE, and hematoma between the ﬁbrin sealant and control
groups. The analysis carried out here suggested that ﬁbrin sealant
use should be efﬁcacy and safety indicated in patients; therefore, a
large and well-designed randomized controlled trial is needed to
investigate the risks and beneﬁts of the use of ﬁbrin sealant.
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